NDAORALCAPSULE
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
CAMZYOS (mavacamten) by Bristol Myers Squibb is cardiac myosin inhibitors [moa]. First approved in 2022.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAMZYOS (mavacamten) is an oral cardiac myosin inhibitor approved by the FDA in April 2022 for treating hypertrophic cardiomyopathy (HCM). It works by selectively inhibiting cardiac myosin, reducing the hypercontractility that characterizes HCM and improving symptoms and cardiac function.
$0.105BPart D
Peak9.6 years to LOEProduct is in peak commercial phase with ~12.7K claims and $105M Part D spending in 2023; team expansion and specialist roles are active.
Mechanism of Action
Cardiac Myosin Inhibitors
Pharmacologic Class:
Cardiac Myosin Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Started May 2026
40 enrolled
Hypertrophic Cardiomyopathy (HCM)
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)
Started Feb 2026
36 enrolled
Cardiomyopathy
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
Started Jan 2026
500 enrolled
Hypertrophic Cardiomyopathy
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
Started Jan 2026
362 enrolled
Obstructive Hypertrophic Cardiomyopathy (oHCM)
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
Started Sep 2025
50 enrolled
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Worked on CAMZYOS at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.